Table 1.

Clinical trials of large surface area microparticle (LSAM) taxanes

Study ID	NCT number	n	Route of administration	Study title	Study statusa
LSAM Docetaxel (LSAM-DTX)
NANODOCE-2017–02	NCT03636256	36	Direct injection to the bladder wall and intravesical instillation	Phase 1/2 Trial Evaluating the Safety and Tolerability of NanoDoce® Injection and Intravesical Instillation in Subjects With Urothelial Carcinoma [12]	Completed
LSAM Paclitaxel (LSAM-PTX)
HSC#1114	NCT00666991	21	Intraperitoneal	Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients with Peritoneal Cancers [6]	Completed
NANOPAC-2016–01	NCT03029585	10	Intraperitoneal	Phase II Study of Four Dose Levels of Intraperitoneal NanoPac Plus IV Carboplatin and Paclitaxel in Patients With Epithelial Ovarian Cancer Undergoing Cytoreductive Surgery [7]	Completed
NANOPAC-2016–02	NCT03077659	16	Intraprostatic injection	Phase IIa Dose Escalation Trial of NanoPac Focal Therapy for Prostate Cancer in Subjects Undergoing Radical Prostatectomy [4]	Completed
NANOPAC-2017–01	NCT03188991	19	Intracystic injection	A Trial Evaluating Escalating Doses and the Safety of Intracystic Injection of NanoPac in Subjects with Mucinous Cystic Pancreatic Neoplasms	Completed
NANOPAC-2016–05	NCT03077685	54	Intratumoral injection	Phase IIa Trial Evaluating the Safety of Intratumoral Injection of NanoPac in Subjects with Locally Advanced Pancreatic Adenocarcinoma	Active, not recruiting
NANOPAC-2019–01	NCT04221828	1	Intratumoral injection	Phase 2 Trial of NanoPac Focal Therapy for Prostate Cancer in Subjects Undergoing Radical Prostatectomy	Terminated
NANOPAC-2020–01	NCT04314895	18	Intratumoral injection	Phase 2 Trial Evaluating the Safety and Tolerability of Intratumoral Injections of NanoPac® with Standard of Care Therapy in Subjects with Lung Cancer	Active, not recruiting

^aStudy status current as of 4 August 2022